These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 31725331)

  • 21. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
    Viel T; Monfared P; Schelhaas S; Fricke IB; Kuhlmann MT; Fraefel C; Jacobs AH
    Mol Ther; 2013 Mar; 21(3):570-9. PubMed ID: 23319055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
    Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED
    J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH; Jiao BH; Wang CY; Wu JL
    CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
    Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
    J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
    Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
    Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z
    Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
    Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
    CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.
    Chen X; Zhang M; Gan H; Wang H; Lee JH; Fang D; Kitange GJ; He L; Hu Z; Parney IF; Meyer FB; Giannini C; Sarkaria JN; Zhang Z
    Nat Commun; 2018 Jul; 9(1):2949. PubMed ID: 30054476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
    Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
    Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.